Article List

WPRIM Management System> DCMS> Clinical and Molecular Hepatology> 2022> 28> 2

Volume: 28 Issue: 2

1. Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles	Page:181—182
2. Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs	Page:269—272
3. Acute on chronic liver failure in cirrhosis	Page:273—275
4. Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area	Page:242—253
5. Surgical resection versus ablation for early hepatocellular carcinoma: The debate is still open	Page:174—176
6. Reply: Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis	Page:267—268
7. Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study	Page:196—206
8. Galectin-3 inhibits cardiac contractility via a tumor necrosis factor alpha-dependent mechanism in cirrhotic rats	Page:232—241
9. Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis	Page:265—266
10. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis	Page:254—264
11. Cost-effectiveness of chronic hepatitis C screening and treatment	Page:164—173
12. Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients	Page:183—195
13. Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma	Page:207—218
14. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region	Page:150—163
15. Approaches to quantifying hepatitis B virus covalently closed circular DNA	Page:135—149
16. The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls	Page:121—134
17. Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis	Page:177—180
18. Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis	Page:219—231